Compare JetBlue Airways Corporation (JBLU) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JetBlue Airways Corporation vs Novo Nordisk A/S — how do they compare? JetBlue Airways Corporation trades at $3.85 (market cap $1.48B), while Novo Nordisk A/S trades at $38.62 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 111.7× JetBlue Airways Corporation's market cap, and Novo Nordisk A/S pays a 4.71% dividend while JetBlue Airways Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold JetBlue Airways Corporation for 44 Days and Novo Nordisk A/S for 116 Days on average.
| JBLU | NVO | |
|---|---|---|
Market Cap | $1.48B | $165.31B |
Volume | 30,275,693 | 11,432,838 |
Sector | Industrials | Health |
52-Week High | $6.46 | $63.98 |
52-Week Low | $3.92 | $35.29 |
Typical Hold Time | 44 Days | 116 Days |
Enterprise Value | $8.84B | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JetBlue (JBLU) trades at $3.86, down 2.77% today, reflecting persistent bearish technical signals and weak earnings. The company reported a net loss of $602 million in 2025, with negative profit margins and declining revenue. Recent news includes route expansion to Colombia but also reduced capacity guidance due to weather and fuel costs. Technical indicators are bearish, with the stock trading near support levels.
The outlook remains challenging with high debt levels and consistent losses. Analyst consensus is mixed but leans hold, with a $5.89 price target suggesting potential upside if operational improvements materialize. Key risks include elevated fuel prices, competitive pressure, and macroeconomic sensitivity. Investment appeal is limited to speculative recovery bets amid ongoing fundamental headwinds.
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
